A part of Merck

Cartuchos Viresolve NFP

Viresolve NFP filters with Viresolve NFP (Normal Flow Parvovirus) membranes clear parvovirus from recombinant or human plasma sources, without compromising flow rates.

Descripción

Especificaciones

Información para pedidos

    Documentation

    Folleto

    Cargo
    Pod filter design enables integrity testing of large area depth filters

    Licencias necesarias e Información técnica

    Cargo
    Application Note - Ensuring Compliance: Regulatory guidance for virus clearance validation
    Millipore‘s Three-Tier Approach to Assuring Integrity of Viresolve® NFP Filters
    Optimizing Viral Clearance Processes
    SMART Technology
    Technical Brief: Viresolve® Prefilter: Extractables Characterization
    The Vmax Nomograph Reference tool for Filter Sizing
    Viral filtration of plasma-derived human IgG

    Ficha técnica

    Cargo
    Provantage™ Services - Viral Clearance Validation Services
    Viresolve® NFP Filters - Fast, reliable parvovirus removal

    Póster

    Cargo
    The Use of Size Exclusion Composite Membrane to Remove TSE Infectious Particles from a Model Protein Solution Filtration

    Referencias bibliográficas

    Visión general referencias
    Validation of Virus Filtration
    Carter, Jeff and Herb Lutz
    BioProcess International January 2003: 52-62 2003

    Removal of prion challenge from an immune globulin preparation by use of a size-exclusion filter
    VAN HOLTEN Robert W; AUTENRIETH Stephen; BOOSE Jeri Ann; HSIEH W T; DOLAN Sherri
    Transfusion : (Philadelphia, PA), 2002, 42 (8) 999-1004 2002

    An overview of viral filtration in biopharmaceutical manufacturing
    Jeffrey Carter and Herbert Lutz, Millipore Corporation, Bedford, MA, USA; European Journal of Parenteral Sciences 2002; 7(3): 72–78 © 2002 Parenteral Society
    European Journal of Parenteral Sciences 2002; 7(3): 72–78 © 2002 Parenteral Society 2002

    Development and Qualification of a Novel Virus Removal Filter for Cell Culture Applications
    Shengjiang Liu, Mark Carroll, Raquel Iverson, Christine Valera, Joann Vennari, Kimberly Turco, Robert Piper, Robert Kiss, Herbert Lutz
    Biotechnology Progress 2000

    Filtration and the Removal of Viruses from Biopharmaceuticals
    Levy, Richard V., Michael W. Phillips, and Herbert Lutz
    Chapter 20 in Filtration in the Biopharmaceutical Industry. New York: Marcel Dekker, Inc., 1998. 1998

    A Validatible Porosimetric Technique for Verifying the Integrity of Virus-Retentive Membranes
    Michael W. Phillips and Anthony J. DiLeo Advanced Separations Research Department, Millipore Corporation, 80 Ashby Road, Bedford MA 0 1 730, U.S.A.
    Biologicals. 1996 Sep;24(3):243-53. 1996

    High Resolution Removal of Virus From Protein Solutions Using A Membrane of Unique Structure
    DiLeo, Anthony J., Anthony E. Allegrezza, and Stuart E. Builder
    Bio/Technology (February 1992): 182-188; RP002 1992

    Preguntas frecuentes

    PreguntaRespuesta
    What is the hold-up volume of an Optiscale 25 NFP ? Millipore does not have a published specification for the hold up volume for an Optiscale 25 NFP capsule. The approximate hold up volume is 300 ul.

    Manuales del usuario

    Cargo
    Viresolve® NFP Filters

    Productos y aplicaciones relacionados

    Familias de productos

    Productos relacionados por: Application Facete

    Productos relacionados por: Brand Facete

    Categorías

    Biopharmaceutical Manufacturing > Downstream Processing > Virus Safety > Virus Filtration > Viresolve Pro & Pro+ > Viresolve NFP